▲ +76.78% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Solid Biosciences in the last 3 months. The average price target is $6.70, with a high forecast of $12.50 and a low forecast of $2.00. The average price target represents a 76.78% upside from the last price of $3.79.
The current consensus among 5 investment analysts is to buy stock in Solid Biosciences.
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.